Optinose announced that it has appointed R. John Fletcher to its Board of Directors as a Class III director. Prior to founding Fletcher Spaght, John was a Senior Manager at The Boston Consulting Group, advising a broad range of companies in healthcare and high technology industries.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 USD | +2.70% | -2.59% | -12.40% |
05-14 | Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.40% | 161M | |
+38.15% | 727B | |
-7.40% | 354B | |
+15.93% | 328B | |
-0.13% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+4.06% | 164B | |
-1.67% | 164B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- Optinose Announces Appointment of R. John Fletcher to its Board of Directors as a Class III Director